EI
Endo, Inc. (NDOI)·Q4 2024 Earnings Summary
Executive Summary
- Q4 revenue was $467.5M, down 6% year over year; GAAP EPS was -$4.59, Adjusted EBITDA was $163.9M, and Adjusted Net Income was $70.5M .
- Branded segment held flat y/y at $246.9M, with XIAFLEX driving $147.9M; XIAFLEX volume rose ~8% y/y despite the prior-year one-time reserve reversal, highlighting resilient demand .
- FY2025 guidance introduced numeric ranges: revenue $1.775–$1.860B, Adjusted EBITDA $620–$650M; assumptions include Adjusted Gross Margin ~64% and Adjusted OpEx $590–$610M .
- Corporate catalyst: announced definitive agreement to combine with Mallinckrodt, targeting pro forma 2025 revenue of ~$3.6B and Adjusted EBITDA of ~$1.2B with at least $150M annual synergy run-rate by Year 3 .
- No standalone Q4 earnings call transcript was published; the Company hosted a joint transaction call in lieu of its Q4 earnings call .
What Went Well and What Went Wrong
What Went Well
- XIAFLEX hit a record $516M in 2024 (+9% y/y) and delivered $147.9M in Q4, with ~8% y/y volume growth; “We ended the year strong… XIAFLEX® annual revenues exceeding $500 million for the first time…” — Scott Hirsch, Interim CEO .
- Adjusted gross margin improved y/y to 64.0% in Q4 (vs. 62.5% in Q4’23), supported by mix and cost actions .
- Sterile Injectables execution: launched three products in Q4 including ADRENALIN ready-to-use (RTU) premixed epinephrine bags—the first FDA-approved manufacturer-prepared epinephrine premixed IV bag—bolstering pipeline and hospital RTU portfolio .
What Went Wrong
- Sterile Injectables pressured by competition: segment down 4% y/y; VASOSTRICT down 41% y/y in Q4, partially offset by resolution of prior supply disruptions .
- Generics down 20% y/y in Q4 (dexlansoprazole pressure); broader competitive headwinds persisted across multiple generic products .
- GAAP results impacted by non-cash charges: asset impairment of $243.6M and higher interest/tax drove GAAP net loss of -$349.3M; operating cash flow fell to $30M vs. $115M in Q4’23 .
Financial Results
Consolidated P&L and Margins (oldest → newest)
Segment and Key Product Breakdown ($M) (oldest → newest)
KPIs and Balance Sheet
Guidance Changes
Note: FY2025 guidance includes International Pharmaceuticals and will be updated after divestiture completion .
Earnings Call Themes & Trends
Management Commentary
- “We ended the year strong, with XIAFLEX® annual revenues exceeding $500 million for the first time and the successful launch of ADRENALIN® ready-to-use premixed bags,” — Scott Hirsch, Interim CEO .
- ADRENALIN RTU premixed epinephrine bags: “The first-ever ready-to-use epinephrine premixed bag represents an advancement… provides greater workflow efficiency, saves time, and reduces the risk of medication error,” — Scott Sims, SVP & GM, Endo Injectable Solutions & Generics .
- Competitive pressures acknowledged across generics and VASOSTRICT; adjusted margin improved due to segment/product mix .
Q&A Highlights
- The Company did not publish a standalone Q4 2024 earnings call transcript; a joint transaction call with Mallinckrodt was hosted instead in lieu of the previously scheduled Q4 earnings calls, limiting available Q&A detail for the quarter .
Estimates Context
- Wall Street consensus (S&P Global) for Q4 2024 EPS and revenue was unavailable due to a mapping issue; therefore, we cannot present beat/miss analysis versus S&P consensus at this time. Values retrieved from S&P Global.*
- Given the absence of S&P consensus, we highlight reported results only: revenue $467.5M, GAAP EPS -$4.59, Adjusted EBITDA $163.9M .
Key Takeaways for Investors
- Branded momentum and XIAFLEX durability underpin core earnings power; Q4 volume rose ~8% y/y and 2024 XIAFLEX hit a record $516M, supporting FY2025 branded guidance of $895–$920M .
- Mix and cost actions lifted adjusted gross margin to 64% in Q4; sustaining margin gains will hinge on portfolio mix and sterile/generics pricing dynamics .
- Sterile Injectables competitiveness remains a watch item (VASOSTRICT -41% y/y), but RTU product innovation (ADRENALIN bags) and resolved supply issues should help stabilize trajectory .
- Generics exposure continues to face structural price competition; segment guidance ($450–$475M FY2025) is calibrated for ongoing pressure .
- Balance sheet and cash generation require monitoring: Q4 operating cash flow fell to $30M amid higher interest and taxes; term loan repricing reduces cash interest by ~$8M annually but post-exit financing costs remain elevated .
- Strategic combination with Mallinckrodt is a material catalyst: expected scale, $75M Year 1 synergies and ≥$150M run-rate by Year 3 could reset earnings power and capital allocation flexibility .
- Near term: focus on execution in branded growth, sterile launches, and synergy capture; medium term: combination-driven scale and portfolio breadth may improve durability and valuation if integration and separation plans (sterile/generics) proceed as envisioned .